These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25781618)

  • 1. Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.
    Riccio E; Sabbatini M; Bruzzese D; Capuano I; Migliaccio S; Andreucci M; Pisani A
    PLoS One; 2015; 10(3):e0118174. PubMed ID: 25781618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
    Sánchez-Álvarez JE; Rodríguez-Suárez C; Coronel-Aguilar D; González-Díaz I; Núñez-Moral M; Peláez-Requejo B; Fernández-Viña A; Quintana-Fernández A
    Nefrologia; 2013 Jan; 33(1):70-6. PubMed ID: 23364628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
    Coyne DW; Goldberg S; Faber M; Ghossein C; Sprague SM
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1620-6. PubMed ID: 24970869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of paricalcitol on urinary calcium in patients with chronic kidney disease stages 2 - 4.
    Martinez-Fernandez I; Saracho R
    Clin Nephrol; 2015 Apr; 83(4):201-7. PubMed ID: 25707454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
    Susantitaphong P; Nakwan S; Peerapornratana S; Tiranathanagul K; Katavetin P; Srisawat N; Praditpornsilpa K; Eiam-Ong S
    BMC Nephrol; 2017 Jan; 18(1):19. PubMed ID: 28088187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol.
    Afsar B; Agca E; Turk S
    J Clin Pharmacol; 2015 Nov; 55(11):1280-5. PubMed ID: 26032009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
    Teng M; Wolf M; Lowrie E; Ofsthun N; Lazarus JM; Thadhani R
    N Engl J Med; 2003 Jul; 349(5):446-56. PubMed ID: 12890843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paricalcitol and endothelial function in chronic kidney disease trial.
    Zoccali C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Politi R; Tripepi G; Ghiadoni L; Thadhani R; Mallamaci F
    Hypertension; 2014 Nov; 64(5):1005-11. PubMed ID: 25259743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.
    Nuijten M; Andress DL; Marx SE; Sterz R
    Curr Med Res Opin; 2009 May; 25(5):1221-34. PubMed ID: 19335321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.
    Coyne DW; Andress DL; Amdahl MJ; Ritz E; de Zeeuw D
    Nephrol Dial Transplant; 2013 Sep; 28(9):2260-8. PubMed ID: 23787544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium balance during calcitriol and paricalcitol administration in healthy humans.
    Hafner V; Rutsch C; Ding R; Heinrich T; Diedrichs L; Schmidt-Gayk H; Walter-Sack I; Bommer J; Mikus G
    Int J Clin Pharmacol Ther; 2008 Mar; 46(3):131-5. PubMed ID: 18397683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.
    Sprague SM; Lerma E; McCormmick D; Abraham M; Batlle D
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S51-6. PubMed ID: 11689388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
    J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D receptor activation by paricalcitol and insulin resistance in CKD.
    Spoto B; Pizzini P; Cutrupi S; Tripepi G; Curatola G; Mallamaci F; Zoccali C
    Nutr Metab Cardiovasc Dis; 2018 Mar; 28(3):291-297. PubMed ID: 29307660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
    Dobrez DG; Mathes A; Amdahl M; Marx SE; Melnick JZ; Sprague SM
    Nephrol Dial Transplant; 2004 May; 19(5):1174-81. PubMed ID: 15004264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol.
    Repo JM; Rantala IS; Honkanen TT; Mustonen JT; Kööbi P; Tahvanainen AM; Niemelä OJ; Tikkanen I; Rysä JM; Ruskoaho HJ; Pörsti IH
    Kidney Int; 2007 Oct; 72(8):977-84. PubMed ID: 17667981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.
    Thethi TK; Bajwa MA; Ghanim H; Jo C; Weir M; Goldfine AB; Umpierrez G; Desouza C; Dandona P; Fang-Hollingsworth Y; Raghavan V; Fonseca VA
    J Diabetes Complications; 2015 Apr; 29(3):433-7. PubMed ID: 25633573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.